Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019;20(1):6-7.
doi: 10.1080/15384047.2018.1507260. Epub 2018 Oct 17.

Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care

Amanda Nizam  1 , Jeanny B Aragon-Ching  2
Affiliations
Comment

Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care

Amanda Nizam et al. Cancer Biol Ther. 2019.

Abstract

Nivolumab is a programmed death 1 (PD-1) inhibitor currently approved as second-line treatment for advanced renal cell carcinomas (RCC) after failure of standard antiangiogenic treatment. Motzer et al. have recently published in the New England Journal of Medicine the findings of CheckMate 214 trial, using nivolumab and ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor, versus sunitinib in previously untreated advanced RCC. The combination demonstrated a higher 18-month overall survival rate of 75% versus 60%, and a higher objective response rate of 42% versus 27%, for the combination in favor over sunitinib monotherapy. These results herald the rapidly changing role of immune checkpoint inhibitor therapy as first-line treatment for metastatic RCC.

Keywords: Immune Checkpoint Inhibitors; Metastatic Renal cell Cancer; ipilimumab; nivolumab; sunitinib.

PubMed Disclaimer

Comment on

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.

References

    1. Kidney and Renal Pelvis Cancer - Cancer Stat Facts [Internet] [accessed 2018 Jun 23]. https://seer.cancer.gov/statfacts/html/kidrp.html.
    1. Motzer RJ, Jonasch E, Agarwal N. NCCN guidelines: kidney cancer (Version 4.2018) [Internet]; 2018. [accessed 2018 Jun 23]. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
    1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813. doi:10.1056/NEJMoa1510665. - DOI - PMC - PubMed
    1. Postow MA, Callahan MK, Wolchok JD.. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982. doi:10.1200/JCO.2014.59.4358. - DOI - PMC - PubMed
    1. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–1290. doi:10.1056/NEJMc1711583. - DOI - PMC - PubMed